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Rachel V. McCarter1, Patrick Nicol1, Jay K. Chhablani2, Mohammed Abdul Rasheed3, Kiran Kumar Vupparaboina3,
Thomas J. MacGillivray4, Mark Harbinson5, Alexander P. Maxwell1, Ruth E. Hogg1 and Gareth J. McKay1*
Abstract
Background: Tissue derived biomarkers may offer utility as indicators of accumulated damage. Reduced thickness
of retinal neuronal tissue and the vascular choroid have previously been associated with vascular damage and
diabetes. We evaluated associations between retinal thickness, retinal microvascular and choroidal measures, and
renal function in a population with a high burden of comorbidity.
Methods: Participants were recruited from nuclear cardiology or renal medicine clinics. Retinal and choroidal
thickness were measured from spectral-domain optical coherence tomograms. Retinal microvascular parameters
were assessed from digital fundus photographs using a semi-automated software package. Main Outcome Measure:
Chronic kidney disease (CKD) categorised as: CKD stages 1–2, eGFR ≥60 ml/min/1.73m2; CKD stage 3, eGFR 30–59
ml/min/1.73m2, and CKD stages 4–5, eGFR ≤29 ml/min/1.73m2.
Results: Participants (n = 241) had a mean age of 65 years and a mean eGFR of 66.9 ml/min/1.73m2. Thirty–nine %
of the cohort had diabetes and 27% were using diuretics. Thinning of the inner retina and changes to its
microvascular blood supply were associated with lower eGFR and CKD stages 4 and 5, while no associations were
found between the outer retinal layers or their choroidal blood supply and CKD of any stage. These associations
remained following adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body
mass index, and sex.
Conclusions: Inner retinal thinning and retinal microvascular variation is associated with advanced CKD (stages 4 &
5) independent of important confounding factors, but not with earlier stage CKD (stage 3) and, therefore, its utility
as a biomarker for early CKD is not supported in this study.
Keywords: Renal function, Chronic kidney disease, Retina, Retinal microvasculature, Choroid, Retinal thickness,
Choroidal volume, Choroidal vascularity index
Background
Chronic kidney disease (CKD) is a major global health
concern estimated to affect between 3 and 18% of the
population [1, 2], resulting in a substantial economic
burden [3–5] and reduced quality of life [6, 7]. Incidence
and prevalence rates for CKD are predicted to increase
significantly over the coming decades given rising obes-
ity rates and ageing populations [8]. As such, non-
invasive, early-stage detection methods would offer
significant clinical utility for identification of persons
with CKD so that targeted interventions could be offered
to reduce renal decline [9].
Despite the availability of several indicators of renal
function and damage, such as serum creatinine, cystatin
C, and proteinuria, the ability to identify those at great-
est risk of future renal decline is limited [10]. The use of
a variety of circulating and genetic biomarkers has of-
fered improved CKD detection and risk prediction [11].
Tissue derived biomarkers provide utility as indicators of
accumulated damage, such as damage to the vasculature
resulting from non-traditional CKD risk factors [12–16],
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however they are typically less amenable to non-invasive
assessment [17].
Improved retinal imaging modalities and analysis soft-
ware has resulted in reported associations between ret-
inal microvascular variation and renal function,
independent of hypertension and diabetes [18–23]. Such
associations may reflect systemic vascular effects and
reno-vascular damage [24]. Indeed, overlapping physi-
ology between the cells of the renal and ocular microcir-
culation, including specialised cell types such as retinal
pericytes and renal mesangial cells, highlight the poten-
tial for similar pathological pathways in both the eye and
the kidney [24]. More recently, evaluation of retinal
thickness through non-invasive optical coherence tom-
ography (OCT) has been considered as a potential bio-
marker for kidney damage [25].
The retina consists of multiple neuronal layers
which can be imaged non-invasively using OCT. Vari-
ability in the thickness of the retinal layers has been
associated with several chronic conditions, including
diabetes mellitus [26–28] and hypertension [29], both
major contributory risk factors for CKD. Recent asso-
ciations between CKD and thinning of the retinal and
adjacent vascular choroidal layers were reported using
OCT in a population without diabetes or cardiovascu-
lar disease (CVD) [25]. However, the choroidal vascu-
lature supplies only the outer layers of the retina,
with the inner layers supplied by the retinal microvas-
culature. A study examining the concordance between
differences in the thickness of the individual layers of
the retina and their specific vascular supply in associ-
ation with CKD is warranted. The aim of this study
was to evaluate retinal thickness and microvascular
measures in association with renal function in a
population with a high burden of comorbidity, inde-
pendent of important confounding factors.
Methods
A cross-sectional analysis of participants who
attended the nuclear cardiology and renal medicine
clinics at the Royal Victoria and Belfast City Hospitals
was undertaken between September 2015 and March
2017. Patients attending the nuclear cardiology clinic
have cardiovascular risk factors or cardiovascular dis-
ease, and may be at risk of CKD; as such, they form
a population where non-invasive assessment regarding
CKD may be of value. Inclusion criteria were partici-
pant age ≥ 18 years and ability to provide informed
consent. Ethics Committee approval was obtained
from the Office for Research Ethics Committees
Northern Ireland (Study ID 14/NI/1132) and con-
formed to the guidelines of the 1975 Declaration of
Helsinki.
Assessment of CKD status
Serum creatinine values were obtained from NHS la-
boratory measurements taken through routine clinical
assessment and estimated glomerular filtration rate
(eGFR) was calculated using the CKD-EPI equation as a
measure of renal function [30]. CKD was categorised as
follows: CKD stages 1–2, eGFR ≥60ml/min/1.73m2;
CKD stage 3, eGFR 30–59ml/min/1.73m2, and CKD
stages 4–5, eGFR ≤29ml/min/1.73m2.
Image acquisition
Images were captured using spectral domain optical co-
herence tomography (SD-OCT) (SPECTRALIS® HRA +
OCT imaging platform, Heidelberg Engineering Ltd.
Hemel Hempstead, Hertfordshire, United Kingdom) fol-
lowing pupil dilation by administration of a single drop
of 1% tropicamide. Posterior pole scans were acquired in
high-speed mode employing 768 A-scans per B-scan,
over a 9.2 × 7.6 mm (30°× 25°) area, with the fovea
remaining central. Sixty-one horizontal B-scans were ac-
quired using automatic real-time tracking (ART) set to
9, with a gap of 120 μm between B-scans. Scans with sig-
nificant artefacts or substantial mirror edge were dis-
carded. The choroid was imaged through SD-OCT
enhanced depth imaging (EDI) also using the SPECTRA-
LIS® HRA +OCT imaging platform (Heidelberg Engin-
eering Inc.) in high-speed mode with a 30°× 25° EDI
volume scan, for 19 sections, with ART set to 9.
Image processing and segmentation
Fovea detection and automated algorithmic segmenta-
tion of the retina into constituent layers for retinal thick-
ness assessment was performed using the Heidelberg
Eye Explorer (HEYEX, version 1.9.17.0.). Constituent
layers that comprised the overall retinal thickness in-
cluded the inner retinal layer (IRL), outer retinal layer
(ORL), nerve fibre layer (NFL), ganglion cell layer
(GCL), inner plexiform layer (IPL), inner nuclear layer
(INL), outer plexiform layer (OPL), Henle’s nerve fibre
layer and outer nuclear layer (HNFL-ONL), and retinal
pigment epithelium (RPE) in accordance with the Inter-
national Nomenclature for Optical Coherence Tomog-
raphy (IN*OCT) consensus [31].
Scans were examined and segmentation errors
amended by graders masked to all clinical information
to avoid any potential bias. For each scan, the foveal
centre was identified as the frame including the brightest
foveal reflex and the thickness of the individual layers
was recorded in microns at the point at which the soft-
ware caliper intersected the foveal reflex. Examples of en
face and cross-sectional retinal images are provided with
Early Treatment Diabetic Retinopathy Study (ETDRS)
grid locations noted (Fig. 1). Thickness of the retinal
layers were measured within standardised segments on
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an ETDRS grid centred on the fovea. These segments
describe four quadrants (inferior [I], superior [S], tem-
poral [T], and nasal [N]) for each of two annuli (annulus
1, proximal to the fovea, and annulus 2, distal to the
fovea), in addition to a central/foveal segment (F). Over-
all retinal thickness was measured as the vertical dis-
tance between Bruch’s membrane and the vitreoretinal
interface. Intraclass correlation coefficients were used to
measure the intragrader reliability of retinal thicknesses,
assessed in 10 retinal images by two trained graders.
Mean intraclass correlation coefficient for each ETDRS
segment was calculated as 0.97 (F), 0.99 (N1), 0.95 (N2),
0.99 (S1), 0.98 (S2), 0.99 (T1), 0.99 (T2), 0.99 (I1), 0.95
(I2), indicating excellent inter-operator agreement. For
choroidal measures, the choroidal images were binarised
so that luminal space was represented by dark pixels and
the choroidal stroma was represented by light pixels.
Choroidal vascularity index (CVI) was calculated using a
previously reported algorithm [32].
Retinal microvascular assessment
Fundus photographs were captured using a 45° retinal
fundus camera (Canon CR-DGi; Canon, Tokyo, Japan).
Poor quality images were excluded. Retinal microvascular
parameters (central retinal arteriolar equivalent [CRAE],
central retinal venular equivalent [CRVE], arteriovenous
ratio [AVR], and fractal dimensions) were measured from
digital retinal fundus photographs using VAMPIRE ver-
sion 3.1.4 (Universities of Dundee and Edinburgh,
Scotland). Retinal microvascular parameters were mea-
sured within an annular zone from 1.0 to 1.5 times the
optic disc diameter from the centre of the optic disc.
Statistical analysis
All statistical analyses were performed using IBM
SPSS statistics version 23.0 (IBM Corp., Armonk,
NY). The difference in mean retinal thickness be-
tween CKD categories was assessed using ANOVA
and the Student-Newman-Keuls test was used to
identify differences between CKD categories. Multi-
nomial logistic regression, with CKD in categories
(grouped as stages 1 to 2, 3 and 4 to 5) as the out-
come, was used to test associations between retinal
thickness and CKD category, and associations between
retinal microvascular parameters, CVI, and choroidal
volume and CKD categories. Multivariable linear re-
gression was used to assess associations between ret-
inal thickness and eGFR, with the latter as the
Fig. 1 Retinal images and grid positions: a shows an image of the retina en face. b shows a cross-sectional image with differentiation of the
retinal layers using the HAYEX software. The cross-section of the retina represents the layers directly behind the green line bisecting the en face
image in panel A. The cross hairs in the left hand panel indicate the location of the foveal dip which can be seen as a depression in the centre of
the image in panel B. c indicates the approximate position and size of the ETDRS grid used for reporting retinal thickness. Segment F is centred
over the fovea. The annulus proximal to the fovea (annulus 1) comprises segments; S1 = superior 1; N1 = nasal 1; I1 = inferior 1; T1 = temporal 1.
The annulus distal to the fovea comprises segments; S2 = superior 2; N2 = nasal 2; I2 = inferior 2; T2 = temporal 2. d highlights the locations where
the ETDRS grid segments bisect the retinal image shown in panel B
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outcome measure. Regression models were adjusted
for age, mean arterial blood pressure (MABP), dia-
betes status, low-density lipoprotein (LDL), body mass
index (BMI), and sex. Associations detected in both
eyes were considered significant only if detected bilat-
erally in both left and right eyes.
The data generated during the current study are avail-
able from the corresponding author on reasonable
request.
Results
Consent for OCT imaging was provided by 241 of the
252 study participants. Of these, 18 participant’s images
were of insufficient quality for grading leaving 223 par-
ticipants with measurable images. The mean age of the
population was 65 years (standard deviation [SD] 9.5),
44% were female and the mean BMI was 31.0 kg/m2 (SD
6.4) (Table 1). The mean systolic and diastolic blood
pressures were 136 mmHg (SD 22) and 81mmHg (SD
13) respectively. A high disease burden was evident with
35% prescribed antihypertensive medication and 39%
having diabetes. Mean HbA1c was 53 mmol/mol (SD
18), with 29% of participants taking hypoglycaemic med-
ications. In participants with diabetes, duration of dia-
betes was less than 5 years in 38%, 5–10 years in 26%,
and > 10 years in 32%. Approximately 8% had a history
of cerebrovascular accident. Mean total cholesterol (3.9
mmol/L, SD 1.2), and LDL cholesterol (2.3 mmol/L, SD
1.0) were within the healthy range but 70% of the re-
cruited participants were prescribed statins. Mean eGFR
was 67 ml/min/1.73m2 (SD 25) with 27% of the popula-
tion using diuretics. Smoking status identified 15% of
participants as current smokers and 49% as having never
smoked.
Retinal thickness
Mean retinal thickness values are presented according to
the ETDRS grid configuration (Fig. 1, Table 2). A de-
scriptive map of individual retinal layers for reference
can be found in the consensus statement of the INOCT
group [31]. Mean retinal thickness was significantly
lower in the nasal, superior and annulus 1 inferior seg-
ments in participants with CKD stages 4–5. There were
no significant differences in retinal thickness between
CKD categories for the central/foveal segment, nor for
any of the annulus distal segments (data not shown).
Odds ratios (OR)s and 95% confidence intervals (CI)
were estimated for CKD per μm change in retinal thick-
ness for the full, inner and outer retina according to the
ETDRS segments of annulus 1 with adjustment for age,
MABP, diabetes, LDL, BMI, and sex (Table 3). Stages 1–
2 (defined as eGFR ≥60ml/min/1.73m2) were used as a
reference category. Retinal thickness was not associated
with CKD stage 3 in any ETDRS segments. For instance,
the odds ratio for having CKD stage 3 compared with
1–2 was 1.00 (0.97, 1.02) per μm increase in N1 full ret-
inal thickness. A thicker retina was negatively associated
with CKD stages 4–5 for the nasal, superior and inferior
annulus 1 segments. For example, the odds ratio for hav-
ing CKD stage 4–5 compared with 1–2 was 0.97 (0.94,
0.99) per μm increase in N1 full retinal thickness. ORs
for the full list of retinal layers by ETDRS segment for
both unadjusted and adjusted analyses are provided in
Additional file 1: Table S1. Retinal thickness was also
negatively associated with CKD stages 4–5 in the tem-
poral segment of annulus 2, but there was no significant
association between full retinal thickness and CKD
stages in any other segments. Retinal thickness was not
significantly associated with CKD stages 4–5 in any
other segments in the adjusted models.
In analyses of the inner and outer retinal layers, similar
patterns of association were observed between CKD
stages 4–5 and the inner retinal layer (Table 3), i.e. a
thicker inner retina in the proximal annulus was signifi-
cantly associated with reduced risk of CKD stage 4–5.
Outer retinal thickness was not significantly associated
with CKD in adjusted analyses.
Associations between retinal thickness and retinal
microvascular supply
ORs for CKD stages per μm change in retinal thickness
are presented for layers primarily supplied by the retinal
microvasculature (NFL, GCL, IPL, and INL) for the an-
nulus 1 ETDRS segments in Table 4 with adjustment for
age, MABP, diabetes, LDL, BMI, and sex. Greater IPL
thickness was associated with reduced risk of CKD stage
3–4 in all inner ETDRS segments and GCL thickness
was associated with reduced risk of CKD stage 3–4 in
segments T1 and I1. For example, per μm increase in
thickness of the IPL in segment S1 of the right eye, the
odds ratio for CKD stage 4–5, was 0.89 times that for
stage 1–2 (OR 0.89, 95% CI 0.80, 0.99). The associations
detected between inner and complete retinal thickness
and CKD arose from variation detected in those layers
supported by the retinal microvasculature. Specifically,
in models adjusted for age, MABP, diabetes status, LDL,
BMI, and sex, greater thickness of the GCL (segments
T1 and I1) and IPL (all segments of annulus 1 and seg-
ment F) were associated with reduced risk of CKD stages
4–5.
Associations between retinal thickness and the choroidal
vasculature
ORs for CKD were estimated per μm change for retinal
layers supplied primarily by the choroidal vasculature
(OPL, ONL, RPE) for annulus 1 ETDRS segments with
adjustment for age, MABP, diabetes, LDL, BMI, and sex
(Table 5). No significant associations were detected
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between CKD and any of the outer retinal layers in an-
nulus 1 or 2 in adjusted analyses. Thickness of the foveal
segment of the outer nuclear area was negatively associ-
ated with risk of CKD stages 3–4 following adjustment
for age, MABP, diabetes, LDL, BMI, and sex.
Retinal microvascular and choroidal measures
ORs for CKD per SD change in choroidal and retinal
microvascular parameters are presented (Table 6). No
significant associations were detected between CVI and
CKD. Higher choroidal volumes were significantly asso-
ciated with lower risk of CKD stage 3 in unadjusted ana-
lyses but the association was no longer significant
following adjustment for age, MABP, diabetes, LDL,
BMI and sex. For each SD increase in choroidal volume
in the unadjusted analysis, the odds ratio for CKD stage
3 were 0.55 times that for stage 1–2 (OR 0.55, 95% CI
0.36, 0.83).
Retinal microvascular changes were associated with
CKD. Greater venular diameter (higher CRVE) was asso-
ciated with lower OR for CKD stage 3 in the unadjusted
analysis. For each SD increase in CRVE in the un-
adjusted analysis, the odds ratio for CKD stage 4–5 were
0.67 times that for stage 1–2 (OR 0.67, 95% CI 0.46,
0.98). No significant associations were detected between
retinal arteriolar calibre (CRAE) and CKD. However,
AVR (the ratio between arteriolar and venular calibre)
was positively associated with CKD stage 3 in both un-
adjusted and adjusted analyses and CKD stages 4–5 in
the unadjusted model only. Arteriolar fractal dimension
was negatively associated with risk of CKD stages 4–5 in
both adjusted and unadjusted analyses, and CKD stage 3
in the unadjusted analysis only. Venular fractal dimen-
sion was not significantly associated with CKD stage 3,
but was negatively associated with risk of CKD stages 4–
5 in both adjusted and unadjusted analyses.
Discussion
We assessed associations between the thickness of the
retinal layers measured using SD-OCT, and CKD stages
in a population with multiple comorbidities. Thinner
retinas were associated with CKD stages 4–5. For
Table 1 Participant characteristics
Variable Population value
Age, years, mean (SD) 65.3 (9.5)
Female, n (%) 106 (44)
eGFR, ml/min/1.73m2, mean (SD) 67 (25)
Weight, Kg, mean (SD) 89.0 (20.1)
BMI, kg/m2, mean (SD) 31.0 (6.4)
Hypertension, n (%) 157 (65)
SBP, mmHg, mean (SD) 136 (22)
DBP, mmHg, mean (SD) 81 (13)
MABP (1/3 SBP + 2/3 DBP), mmHg, mean (SD) 99 (13)
HbA1c mean, mmol/mol, (SD) 53 (18)
Total Cholesterol, mean, mmol/L (SD) 3.92 (1.18)
HDL, mean, mmol/L (SD) 1.33 (0.45)
LDL, mean, mmol/L (SD) 2.28 (0.97)
Troponin, mean, mmol/L (SD) 17.8 (28.9)
CRP, mean, mmol/L (SD) 9.5 (35.6)
Pack Years, mean (SD) 39.8 (35.0)
CVD, n (%) 100 (41.5)
Diabetes mellitus, n (%) 93 (39)
Type 1, n (%) 13 (5)
Type 2, n (%) 80 (33)
Insulin, n (%) 29 (31)
Previous CVA, n (%) 19 (8)
Antihypertensives, n (%) 83 (35)
Hypoglycaemics, n (%) 68 (29)
Statins, n (%) 164 (69)
Diuretics, n (%) 63 (27)
NSAIDs, n (%) 12 (5)
Vitamin supplements, n (%) 48 (20)
Rheumatoid arthritis, n (%) 10 (9)
Hypertension treatment, n (%)
None 78 (33)
< 5 years 54 (23)
5–10 years 38 (16)
> 10 years 64 (27)
Smoking, n (%)
Never 119 (49)
Ex 87 (36)
Current 35 (15)
Alcohol, n (%)
none 134 (56)
1–5 units 38 (16)
6–10 units 28 (12)
15–20 units 25 (10)
> 25 units 12 (5)
Table 1 Participant characteristics (Continued)
Variable Population value
QRISK2 score, n (%)
1 38 (34)
2 35 (31)
3 38 (34)
SD Standard deviation, eGFR estimated glomerular filtration rate, SBP Systolic
blood pressure, DBP Diastolic blood pressure, MABP Mean arterial blood
pressure, HbA1c Glycated haemoglobin A1c, HDL High density lipoprotein, LDL
Low density lipoprotein, CRP C reactive protein, CVD Cardiovascular disease,
CVA Cerebrovascular accident, NSAIDs Non-steroidal anti-inflammatory drugs
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example, per μm increase in thickness of the full retina
in segment N1, the odds of CKD stage 4–5 were reduced
by 3% per μm (i.e. OR of 0.97) compared with CKD
stage 1–2. Differences in retinal thickness were primarily
as a consequence of lower thickness of the inner retinal
layers. In particular, thinner GCL and IPL were associ-
ated with CKD stages 4–5, with associations being
largely limited to the proximal macular segments of an-
nulus 1 as differentiated by the ETDRS grid. These asso-
ciations were significant following adjustment for a
range of important potential confounding factors such
as age, blood pressure, diabetes status, LDL, BMI, and
sex and support and expand previously reported findings
[25]. Of note, significant associations were detected only
within layers supported by the retinal microvascular
blood supply, and not the layers supported by a chor-
oidal blood supply. No significant associations were
found bilaterally between retinal thickness and earlier
stage CKD (CKD stage 3). This finding does not support
the hypothesis that changes to retinal thickness may be
detectible early in the progression of CKD. Collectively
these data suggest that retinal thickness, and in particu-
lar thickness of the IPL and GCL, is lower in those with
CKD stages 4–5 independent of diabetes, blood pressure
and other potential confounding factors.
Similar changes have been reported in studies of dia-
betes and its complications. Thinning of the inner retinal
layers, specifically the IPL, INL, and GCL, within annu-
lus 1 has previously been associated with diabetes in
those with early stages of diabetic retinopathy [33, 34].
Murine models of early diabetes have also shown thin-
ning of the INL and IPL in association with reductions
in retinal ganglion cell numbers coinciding with retinal
neuronal and vascular apoptosis [35], which may reflect
the susceptibility of retinal vascular and neuronal tissues
to similar noxious environments. Similar patterns of ret-
inal apoptosis have also been observed in human retinas
post mortem from individuals with diabetes, including
those without retinal pathology [35].
Potential confounding factors such as age [36–40],
LDL [40], MABP [29], sex [36, 37, 40–42], and BMI [41]
have all been previously associated with retinal thickness
and as such were considered as potential confounders.
These factors are also associated with vascular risk, and
indeed vascular damage has been proposed as a mechan-
ism that contributes to changes in retinal thickness in
Table 2 Mean retinal, inner retinal and outer retinal thickness values for CKD stages 1–2, 3, and 4–5
ETDRS
segment
Right eye Left eye
CKD stages 1–2 CKD stage 3 CKD stage 4–5 ANOVA CKD stages 1–2 CKD stage 3 CKD stage 4–5 ANOVA
Mean thickness μm
(SD)
Mean
thickness
μm (SD)
Mean thickness μm
(SD)
p Mean thickness μm
(SD)
Mean
thickness
μm (SD)
Mean thickness μm
(SD)
p
Full retinal thickness
N1 342 (17) A 339 (21) A 324 (27) B <
0.001*
343 (22) A 341 (26) A 327 (28) B 0.004*
S1 337 (18) A 336 (20) A 320 (26) B <
0.001*
340 (20) A 336 (22) A 321 (28) B <
0.001*
T1 326 (17) 324 (16) 317 (48) 0.14 328 (19) A 325 (19) A 313 (38) B 0.005*
I1 336 (17) A 332 (19) A 319 (28) B <
0.001*
337 (21) A 333 (19) A 318 (27) B <
0.001*
Inner Retinal Layer
N1 261 (17) A 258 (19) A 244 (26) B <
0.001*
262 (21) A 257 (19) B 248 (30) B 0.01*
S1 257 (17) A 256 (19) A 241 (25) B <
0.001*
260 (20) A 255 (19) A 243 (30) B 0.001*
T1 246 (16) 244 (15) 238 (48) 0.19 248 (18) A 245 (18) A 235 (38) B 0.01*
I1 257 (17) A 253 (18) A 240 (28) B <
0.001*
258 (20) A 254 (16) A 241 (27) B <
0.001*
Outer Retinal Layer
N1 81 (3) 81 (4) 80 (3) 0.47 81 (3) 83 (11) 80 (3) 0.06
S1 80 (3) 80 (4) 79 (3) 0.45 80 (3) 81 (7) 79 (3) 0.08
T1 80 (3) 80 (4) 79 (3) 0.29 80 (3) 80 (3) 79 (3) 0.35
I1 79 (3) 79 (4) 79 (4) 0.91 79 (3) 80 (6) 78 (4) 0.15
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal
segment 1, I1 Inferior segment 1, T1 Temporal segment 1. A, B and C indicate groups which are significantly different from each other according to SNK test
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individuals with diabetes. However, the cellular, bio-
chemical and physiological mechanisms that lead to
neural cell loss and vascular changes within the diabetic
retina have still to be fully determined [43, 44]. Given
the cross-sectional nature of this study, the temporality
of events relating to cause and effect in those with CKD
stages 4–5 cannot be established and longitudinal data
would be necessary to determine causality. However, this
study provides novel evidence of these associations with
individual retinal layers, and thus some insight to the
mechanisms behind previously reported changes in ret-
inal thickness in those with CKD [25].
Several studies have reported structural alterations in
the retinal vasculature in association with CKD and re-
duced renal function [18, 19, 23, 45, 46]. Furthermore,
inflammation and hypoxia have been linked to impaired
metabolism in Müller cells which help protect against
ganglion cell apoptosis [47], supporting the hypothesis
that retinal neurodegeneration in those with reduced
renal function may result from vascular impairment.
Vascular impairment may also explain the physical pat-
tern of associations observed. The outer retinal layers re-
ceive nutrients via diffusion from the choroid, while the
inner layers are serviced by the retinal microvasculature.
Consequently, the inner retinal layers are more suscep-
tible to hypoxic injury compared to the outer layers [48].
Hypoxic damage has also been linked to retinal ganglion
cell death mediated by inflammatory cytokines [48],
consistent with the findings of lower GCL thickness in
those with CKD stages 4–5. Indeed, all of the significant
associations detected bilaterally were detected in layers
primarily supplied by the retinal microvasculature and
not the choroid.
The proximal annulus 1, comprising segments S1,
N1, I1, and T1, is in an area approaching the foveal
avascular zone. Segments of the retina proximal to,
but not within, the foveal segment, thus have a
sparser retinal vasculature and are more likely to be
affected. The absence of associations between foveal
thickness and renal status may be as a consequence
of its choroidal blood supply [49] protecting this tis-
sue from susceptibility to hypoxia from retinal vascu-
lar impairment. Associations will also be affected by
the smaller size and partial coverage of the inner ret-
inal layers over this area of the retina [50].
Retinal neurodegeneration in diabetes has been associ-
ated with NFL thinning related to capillary occlusion
and retinal ganglion cell loss [51], and thinner NFLs
have been reported in patients with CKD undergoing
haemodialysis or peritoneal dialysis [52]. It is therefore
unclear why we did not observe lower NFL thickness in
CKD stages 4–5, although a lack of significant variation
in NFL thickness between CKD cases and healthy con-
trols has previously been reported in earlier stages of
CKD [25]. Interestingly, in regression analyses using
eGFR as a continuous outcome variable, we found a
Table 3 Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of
the full retina, inner retina and outer retina
ETDRS
segment
Right eye Left eye
CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2) CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2)
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Full retinal thickness
N1 1.00 (0.97, 1.02) 0.89 0.97 (0.94, 0.99) 0.02* 1.00 (0.98, 1.01) 0.70 0.98 (0.95, 1.00) 0.03*
S1 1.00 (0.98, 1.03) 0.76 0.97 (0.94, 0.99) 0.01* 1.00 (0.98, 1.01) 0.69 0.97 (0.95, 0.99) 0.01*
T1 1.00 (0.98, 1.02) 0.80 0.99 (0.97, 1.01) 0.33 1.00 (0.98, 1.02) 0.83 0.98 (0.96, 1.00) 0.08
I1 1.00 (0.97, 1.02) 0.87 0.97 (0.95, 1.00) 0.02* 1.00 (0.98, 1.01) 0.73 0.97 (0.94, 0.99) 0.01*
Inner Retinal Layer
N1 1.00 (0.97, 1.02) 0.70 0.97 (0.94, 0.99) 0.01* 0.99 (0.97, 1.01) 0.32 0.98 (0.95, 1.00) 0.03*
S1 1.00 (0.98, 1.03) 0.87 0.97 (0.94, 0.99) 0.01* 0.99 (0.98, 1.01) 0.47 0.97 (0.95, 0.99) 0.01*
T1 1.00 (0.98, 1.02) 0.92 0.99 (0.96, 1.01) 0.34 1.00 (0.98, 1.01) 0.71 0.98 (0.96, 1.00) 0.09
I1 1.00 (0.97, 1.02) 0.80 0.97 (0.94, 0.99) 0.02* 0.99 (0.97, 1.01) 0.47 0.97 (0.94, 0.99) 0.01*
Outer Retinal Layer
N1 1.08 (0.96, 1.22) 0.22 1.01 (0.86, 1.18) 0.93 1.12 (0.99, 1.28) 0.08 1.00 (0.85, 1.17) 0.96
S1 1.07 (0.93, 1.22) 0.34 1.00 (0.84, 1.18) 0.96 1.08 (0.96, 1.21) 0.20 0.97 (0.83, 1.13) 0.68
T1 1.10 (0.96, 1.25) 0.19 1.01 (0.84, 1.20) 0.94 1.08 (0.93, 1.26) 0.31 0.99 (0.82, 1.18) 0.90
I1 1.05 (0.92, 1.21) 0.46 1.05 (0.89, 1.25) 0.54 1.09 (0.96, 1.23) 0.18 1.02 (0.88, 1.18) 0.82
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal
segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density
lipoprotein, body mass index, and sex
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significantly thicker NFL bilaterally in the distal tem-
poral segment in association with higher eGFR (Add-
itional file 1: Table S2). In optic disc oedema, the
NFL thickens at an early stage of the pathology but
thins as the disease progresses [53]. Given a lack of
association between NFL and CKD has been reported
in a relatively healthy CKD sample previously [25],
the negative association observed between eGFR and
NFL thickness in this study population with a higher
comorbidity burden may represent the early stages of
neurodegeneration prior to significant axonal loss,
and axonal loss may increase as the pathology de-
velops. NFL thickening, without concomitant thicken-
ing of the other retinal layers (as in our study), has
been reported in inflammatory optic neuropathies
[54] and is not without precedent, although the po-
tential for a type-1 error must be considered. The
temporal segments comprise an area of the retina
which typically has less coverage of arterioles and ve-
nules, being distal from the optic disc, and further
from the main branches of the retinal arcades, which
may increase its susceptibility to vascular damage.
We also assessed choroidal volume and CVI and
detected an association between choroidal volume and
CKD stage 3 in an unadjusted analysis, although this
was no longer significant following adjustment for po-
tential confounders. The association between chor-
oidal volume may be explained by well-known CVD
risk factors (age, sex, BMI, MABP, LDL, and diabetes)
reflecting the vascular nature of this tissue. This find-
ing is consistent with the possible role of the retinal
microvasculature (as opposed to the choroidal circula-
tion) in the inner retinal changes observed and the
lack of outer retinal changes. Moreover, retinal micro-
vascular branching patterns (measured as fractal di-
mension) were significantly associated with CKD
stage. Those with more extensive microvascular
branching had lower risk of CKD stages 4–5.
This study had several strengths including the ability
to control for major confounders such as age, sex, BMI,
diabetes, LDL and MABP. Given that many of the asso-
ciations remained significant following adjustment, it
may be that the observed associations, and previously re-
ported unadjusted associations [25], between retinal
Table 4 Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of
retinal layers supplied by the retinal microvasculature
ETDRS
segment
Right eye Left eye
CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2) CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2)
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Nerve fibre layer
N1 0.99 (0.86, 1.14) 0.88 0.88 (0.74, 1.05) 0.15 1.01 (0.90, 1.13) 0.93 1.00 (0.90, 1.11) 0.95
S1 1.05 (0.96, 1.16) 0.27 1.00 (0.90, 1.11) 0.97 1.03 (0.94, 1.13) 0.52 0.99 (0.89, 1.10) 0.85
T1 0.83 (0.64, 1.06) 0.14 1.04 (0.96, 1.13) 0.35 0.95 (0.77, 1.17) 0.63 1.14 (0.96, 1.36) 0.14
I1 0.97 (0.87, 1.08) 0.58 0.94 (0.84, 1.06) 0.31 1.02 (0.92, 1.13) 0.70 1.00 (0.90, 1.11) 0.94
Ganglion cell layer
N1 1.02 (0.96, 1.09) 0.48 0.93 (0.87, 1.00) 0.04* 1.00 (0.94, 1.07) 0.98 0.94 (0.87, 1.01) 0.08
S1 1.02 (0.95, 1.09) 0.60 0.92 (0.86, 0.99) 0.02* 1.01 (0.94, 1.09) 0.75 0.95 (0.88, 1.03) 0.18
T1 1.01 (0.94, 1.08) 0.87 0.89 (0.82, 0.97) 0.01* 1.01 (0.95, 1.07) 0.74 0.93 (0.87, 0.99) 0.02*
I1 1.02 (0.95, 1.10) 0.57 0.90 (0.83, 0.96) 0.004* 1.03 (0.96, 1.10) 0.47 0.90 (0.84, 0.97) 0.004*
Inner plexiform layer
N1 1.01 (0.92, 1.11) 0.83 0.91 (0.82, 1.00) 0.04* 0.99 (0.91, 1.09) 0.90 0.90 (0.82, 1.00) 0.04*
S1 1.01 (0.92, 1.12) 0.78 0.89 (0.80, 0.99) 0.03* 0.99 (0.89, 1.10) 0.81 0.88 (0.78, 0.99) 0.03*
T1 1.00 (0.90, 1.11) 0.96 0.87 (0.78, 0.98) 0.02* 1.03 (0.93, 1.13) 0.61 0.89 (0.80, 0.99) 0.03*
I1 1.01 (0.90, 1.12) 0.92 0.85 (0.76, 0.96) 0.01* 1.02 (0.92, 1.14) 0.66 0.82 (0.73, 0.93) 0.002*
Inner nuclear layer
N1 0.91 (0.82, 1.02) 0.10 0.9 (0.79, 1.02) 0.11 0.90 (0.81, 1.01) 0.07 0.96 (0.86, 1.06) 0.42
S1 0.92 (0.83, 1.02) 0.11 0.9 (0.80, 1.01) 0.08 0.92 (0.84, 1.01) 0.09 0.88 (0.79, 0.97) 0.01*
T1 0.91 (0.80, 1.03) 0.14 0.87 (0.75, 1.00) 0.06 0.93 (0.83, 1.03) 0.17 0.88 (0.78, 0.99) 0.03*
I1 0.96 (0.86, 1.06) 0.42 0.96 (0.84, 1.08) 0.49 0.93 (0.84, 1.03) 0.16 0.89 (0.79, 1.00) 0.06
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal
segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density
lipoprotein, body mass index, and sex
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thickness and renal function manifest as a consequence
of a CKD specific mechanistic pathway.
The use of SD-OCT and the HEYEX semi-automated
software provided highly reliable measures that enabled
a more sensitive evaluation of the retinal and choroidal
layers than previously reported. Furthermore, the subse-
quent correction by graders blinded to participant char-
acteristics reduced the influence of observer bias in this
study. To the best of our knowledge, this was the first
study to investigate the direct association between such
a broad range of retinal and choroidal layers and eGFR.
SD-OCT provided robust differentiation of the retinal
layers that will help improve our understanding of the
cellular pathways behind the associations observed. SD-
OCT-EDI enabled evaluation of choroidal measures
including choroidal volume and CVI to improve the sen-
sitivity of the choroidal measures [25] that are frequently
affected by unevenness of the choroidal-scleral interface.
We have combined the choroidal measures with retinal
microvascular assessment to provide insight into poten-
tial vascular mediation of retinal thickness associated
with CKD. Moreover, OCT is currently used in the diag-
nosis and evaluation of a variety of retinal conditions,
such as diabetic retinopathy, and thus retinal changes as-
sociated with CKD may be assessed using widely avail-
able technology.
Table 6 Odds ratios for CKD stage 3 and stages 4–5 per standard deviation increase choroidal vascularity index (unit-less), Choroidal
volume (mm3), AVR (unit-less), and fractal dimension
Variable CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2)
OR 95% CI p OR 95% CI p
Choroidal vascularity index 1.37 (0.80, 2.36) 0.25 1.44 (0.78, 2.67) 0.25
Choroidal Volume (mm3) 0.90 (0.55, 1.46) 0.67 0.76 (0.40, 1.44) 0.40
CRAE 0.92 (0.54, 1.55) 0.75 0.66 (0.35, 1.28) 0.22
CRVE 0.66 (0.41, 1.06) 0.08 1.07 (0.55, 2.07) 0.85
AVR 1.67 (1.01, 2.75) 0.05* 0.59 (0.27, 1.26) 0.17
LogFractalDimCa1 1.05 (0.62, 1.79) 0.86 0.45 (0.24, 0.84) 0.01*
LogFractalDimCv1 0.94 (0.58, 1.54) 0.82 0.53 (0.29, 0.94) 0.03*
CI Confidence interval, OR Odds ratio. *significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body mass
index, and sex
Table 5 Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of
retinal layers supplied by the choroidal vasculature
ETDRS
segment
Right eye Left eye
CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2) CKD stage 3 (vs. stage 1–2) CKD stage 4–5 (vs. stage 1–2)
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Outer plexiform layer
N1 1.03 (0.97, 1.10) 0.33 1.03 (0.96, 1.11) 0.45 1.00 (0.94, 1.07) 0.89 1.00 (0.93, 1.08) 0.94
S1 1.02 (0.96, 1.09) 0.46 0.95 (0.86, 1.04) 0.26 1.00 (0.95, 1.06) 0.93 0.93 (0.87, 0.99) 0.03*
T1 1.07 (0.96, 1.20) 0.22 0.93 (0.81, 1.08) 0.34 1.11 (1.02, 1.22) 0.02* 1.01 (0.90, 1.13) 0.84
I1 1.01 (0.94, 1.08) 0.78 1.05 (0.98, 1.14) 0.18 1.04 (0.97, 1.12) 0.24 1.08 (1.01, 1.16) 0.03*
Outer nuclear layer
N1 0.98 (0.94, 1.01) 0.22 0.95 (0.91, 1.00) 0.05* 0.99 (0.96, 1.02) 0.35 0.97 (0.93, 1.01) 0.10
S1 0.99 (0.95, 1.03) 0.52 0.97 (0.92, 1.02) 0.23 0.99 (0.97, 1.02) 0.45 0.99 (0.96, 1.03) 0.61
T1 1.00 (0.96, 1.04) 0.89 1.00 (0.97, 1.04) 0.78 0.98 (0.94, 1.01) 0.20 0.98 (0.95, 1.02) 0.42
I1 0.99 (0.95, 1.03) 0.68 0.96 (0.91, 1.01) 0.10 0.96 (0.92, 1.00) 0.07 0.94 (0.89, 0.98) 0.01*
Retinal pigmented epithelium
N1 1.02 (0.80, 1.30) 0.88 1.00 (0.75, 1.35) 0.98 1.21 (0.96, 1.53) 0.11 1.01 (0.76, 1.35) 0.93
S1 1.09 (0.84, 1.42) 0.51 0.97 (0.70, 1.35) 0.87 1.13 (0.91, 1.39) 0.26 0.77 (0.55, 1.07) 0.11
T1 1.04 (0.80, 1.35) 0.79 1.05 (0.76, 1.44) 0.78 1.09 (0.84, 1.41) 0.53 1.01 (0.74, 1.38) 0.96
I1 0.94 (0.74, 1.20) 0.63 1.00 (0.75, 1.34) 0.99 1.09 (0.91, 1.31) 0.34 0.99 (0.77, 1.29) 0.96
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal
segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density
lipoprotein, body mass index, and sex
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There were several limitations in this study. The cross-
sectional nature of this study does not allow for the
determination of causality of association. eGFR lacks
sensitivity as an indicator of renal decline [55], and so
the clinical relevance of these findings require further
consideration through longitudinal evaluation of changes
in retinal thickness with declining kidney function with
age. Furthermore, the specificity of the observed associa-
tions with the underlying cause of CKD was not exam-
ined. Future studies may investigate the specificity of
changes in retinal thickness with disorders such as dia-
betic nephropathy to determine the value of such retinal
changes in risk stratification. This might inform the use
of more invasive procedures, such as renal biopsy.
Additionally, assessment of proteinuria, underlying
CKD cause, measures of systemic vascular health and
use of diuretics may inform potential mechanisms and
improve predictive capacity. In particular, future work
should consider measures of proteinuria and diuretic use
to determine potential influence on retinal thickness.
Furthermore, because the aetiology of renal decline was
not assessed in the present study, it is unclear whether
patterns of retinal thinning in CKD depend on the
underlying cause of reduced renal function. The effect of
the associations considered are not generalisable to the
general population as recruitment was undertaken in a
clinical setting. CKD is defined clinically as persistently
decreased eGFR of less than 60 mL/min/1.73 m2 for at
least 3 months, and / or persistent proteinuria [55]. This
differs from the definition we used in this study which
relied solely on a single measure of renal function and
associations may therefore be weaker than those in a
study using stricter clinical CKD staging.
Retinal thickness is related to a variety of other condi-
tions. For example, reduced thickness of the retinal gan-
glion cell complex (GCC; a composite retinal layer
comprising the retinal layers containing the ganglion cell
dendritic synapses with bipolar and amacrine cells, the
ganglion cell bodies, and the ganglion cell axons viz., the
IPL, GCL, and NFL respectively) has also been associ-
ated with a variety of ocular diseases in their early stages,
such as glaucoma [56], retinal vessel loss in open-angle
glaucoma [57], and chiasmal compression [58]. Similar
changes have also been reported in early age-related
macular degeneration [59]. This highlights the sensitivity
of these layers to a variety of pathologies and also indi-
cates the need to control for these conditions, where
possible, in future analyses. Choroidal thickness is also
affected by other factors such as diurnal variation and is
affected by fluid intake [60]. We did not record or
control for fluid intake and this may represent an un-
accounted confounding influence. However, all measure-
ments were made in the afternoon, and so diurnal
variation is thought to have had little effect on the
associations observed. Finally, the issue of multiple test-
ing was a limitation. The number of statistical associa-
tions evaluated provides an increased risk of type-1
error. However, we have limited our conclusions and
discussion to reflect associations with bilateral signifi-
cance only in an effort to mitigate such influences.
Conclusion
Reduced retinal thickness, and in particular a thinner
inner retinal layer, was found to be associated with CKD
stage 4–5 independent of other important risk factors
(age, MABP, diabetes status, LDL, BMI and sex). These
associations were limited to layers of the retina supplied
by the retinal microvasculature and to areas immediately
surrounding the foveal zone. These findings do not sup-
port the hypothesis that changes in retinal thickness are
detectible at the earliest stages of CKD, but highlight a
distinct pattern of retinal changes detectable in CKD
stages 4–5. In particular, IPL and GCL thickness are
lower in those with CKD stages 4–5 and occur alongside
changes to retinal microvascular AVR and fractal
dimension.
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